15 May 2024 15:00 BST
Transaction by Person
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on
13 May 2024, Pascal Soriot, Chief Executive Officer, was granted an
award of the Company's ordinary shares of $0.25 each (Ordinary
Shares) under the terms of the AstraZeneca Performance Share Plan
(AZPSP), as detailed in the table below.
This award forms part of the AZPSP award
granted to Mr Soriot on 4 March 2024. As described in AstraZeneca's
2023 Directors' Remuneration Report, it has been made in accordance
with the Directors' Remuneration Policy and amended rules of the
AZPSP approved by shareholders at the Company's 2024 Annual General
Meeting.
|
PDMR
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal Soriot
|
29,474
|
£100.81
|
The AZPSP award is subject to a combination of
performance measures focused on scientific, commercial, financial
and sustainability performance. The performance measures will be
assessed over a three-year performance period (1 January 2024 to 31
December 2026). The Ordinary Shares granted under the AZPSP are
subject to a two-year holding period following the performance
period, and are due to vest on the fifth anniversary of
grant.
Details of the performance measures attached to
the AZPSP award can be found in the Directors' Remuneration Report
within the AstraZeneca Annual Report and Form 20-F Information
2023, which is available on the Company's website at
www.astrazeneca.com/annualreport2023.
Further details are set out in the attached
notification, made in accordance with the requirements of the EU
Market Abuse Regulation (as it forms part of UK law pursuant to the
European Union (Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the
AstraZeneca Performance Share Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£100.81
|
29,474
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
13 May 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC